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Gastric cancer is a leading cause of cancer deaths, but analysis of its molecular and clinical characteristics has been
complicated by histological and aetiological heterogeneity. Here we describe a comprehensive molecular evaluation of
295 primary gastric adenocarcinomas as part of The Cancer Genome Atlas (TCGA) project. We propose a molecular
classification dividing gastric cancer into four subtypes: tumours positive for Epstein–Barr virus, which display recur-
rent PIK3CAmutations, extreme DNA hypermethylation, and amplification of JAK2, CD274 (also known as PD-L1) and
PDCD1LG2 (also knownasPD-L2);microsatellite unstable tumours,which showelevatedmutation rates, includingmuta-
tions of genes encoding targetable oncogenic signalling proteins; genomically stable tumours,which are enriched for the
diffuse histological variant and mutations of RHOA or fusions involving RHO-family GTPase-activating proteins; and
tumours with chromosomal instability, which show marked aneuploidy and focal amplification of receptor tyrosine
kinases. Identification of these subtypes provides a roadmap for patient stratification and trials of targeted therapies.
Gastric cancer was the world’s third leading cause of cancer mortality
in 2012, responsible for 723,000 deaths1. The vast majority of gastric
cancers are adenocarcinomas, which can be further subdivided into
intestinal and diffuse types according to the Lauren classification2. An
alternative system, proposedby theWorldHealthOrganization, divides
gastric cancer intopapillary, tubular,mucinous (colloid) andpoorly co-
hesive carcinomas3. These classification systems have little clinical util-
ity, making the development of robust classifiers that can guide patient
therapy an urgent priority.
Themajority of gastric cancers are associatedwith infectious agents,
including the bacterium Helicobacter pylori4 and Epstein–Barr virus
(EBV). The distribution of histological subtypes of gastric cancer and
the frequencies ofH.pylori andEBVassociatedgastric cancer vary across
the globe5. A small minority of gastric cancer cases are associated with
germline mutation in E-cadherin (CDH1)6 or mismatch repair genes7
(Lynch syndrome), whereas sporadic mismatch repair-deficient gast-
ric cancers have epigenetic silencing ofMLH1 in the context of a CpG
island methylator phenotype (CIMP)8. Molecular profiling of gastric
cancerhasbeenperformedusinggeneexpressionorDNAsequencing9–12,
but has not led to a clear biologic classification scheme.The goals of this
study by The Cancer Genome Atlas (TCGA) were to develop a robust
molecular classification of gastric cancer and to identify dysregulated
pathways and candidate drivers of distinct classes of gastric cancer.
Sample set and molecular classification
We obtained gastric adenocarcinoma primary tumour tissue (fresh fro-
zen) from 295 patients not treated with prior chemotherapy or radio-
therapy (SupplementaryMethods S1). All patients provided informed
consent, and local InstitutionalReviewBoards approved tissue collection.
We used germline DNA from blood or non-malignant gastric mucosa
as a reference for detecting somatic alterations. Non-malignant gastric
samples were also collected forDNAmethylation (n5 27) and expres-
sion (n5 29) analyses. We characterized samples using six molecular
platforms (SupplementaryMethods S2–S7): array-based somatic copy
number analysis, whole-exome sequencing, array-based DNAmethy-
lation profiling,messenger RNA sequencing,microRNA (miRNA) se-
quencing and reverse-phase protein array (RPPA), with 77% of the
tumours tested by all six platforms.Microsatellite instability (MSI) test-
ing was performed on all tumour DNA, and low-pass (,63 coverage)
whole genome sequencing on 107 tumour/germline pairs.
To define molecular subgroups of gastric cancer we first performed
unsupervised clustering on data from each molecular platform (Sup-
plementaryMethods S2–S7) and integrated these results, yielding four
groups (Supplementary Methods S10.2). The first group of tumours
was significantly enriched for high EBV burden (P5 1.53 10218) and
showed extensive DNA promoter hypermethylation. A second group
was enriched forMSI (P5 2.13 10232) and showed elevatedmutation
rates and hypermethylation (including hypermethylation at theMLH1
promoter). The remaining two groups were distinguished by the pres-
ence or absence of extensive somatic copy-number aberrations (SCNAs).
As an alternativemeans to define distinct gastric cancer subgroups, we
performed integrative clustering ofmultiple data types using iCluster13
(SupplementaryMethods S10.3). This analysis again indicated thatEBV,
MSI and the level of SCNAscharacterize distinct subgroups (Supplemen-
tary Fig. 10.3). Based upon these results from analysis of all molecular
platforms, we created a decision tree to categorize the 295 gastric can-
cer samples into four subtypes (Fig. 1a, b) using an approach that could
more readily be applied to gastric cancer tumours in clinical care. Tu-
mourswere first categorized byEBV-positivity (9%), then byMSI-high
status, hereafter called MSI (22%), and the remaining tumours were
distinguished by degree of aneuploidy into those termed genomically
stable (20%) or those exhibiting chromosomal instability (CIN; 50%).
Evaluation of the clinical and histological characteristics of these
molecular subtypes revealed enrichment of the diffuse histological sub-
type in the genomically stable group (40/555 73%, P5 7.53 10217)
(Fig. 1c), an association not attributable to reduced SCNAdetection in
low purity tumours (Supplementary Fig. 2.8). Each subtype was found
throughout the stomach, but CIN tumours showed elevated frequency
in the gastroesophageal junction/cardia (65%,P5 0.012),whereasmost
EBV-positive tumourswere present in the gastric fundus or body (62%,
P5 0.03).Genomically stable tumourswere diagnosed at an earlier age
(median age 59 years, P5 43 1027), whereas MSI tumours were di-
agnosed at relatively older ages (median 72 years, P5 53 1025). MSI
patients tended to be female (56%, P5 0.001), but most EBV-positive
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cases weremale (81%, P5 0.037), as previously reported14.We did not
observe any systematic differences in distribution of subtypes between
patients of East Asian and Western origin (Supplementary Methods
S1.8). Initial outcome data from this cohort did not reveal survival dif-
ferences between the four subgroups (Supplementary InformationS1.7).
EBV-associated DNA hypermethylation
EBV is foundwithinmalignant epithelial cells in 9%of gastric cancers14.
EBV status was determined usingmRNA,miRNA, exome and whole-
genome sequencing, yielding highly concordant results (Supplemen-
tary Fig. 9.7). By contrast, we detected only sporadic evidence of H.
pylori, whichmay reflect the decline of bacterial counts accompanying
the progression fromchronic gastritis to subsequent carcinoma, aswell
as technical loss of luminal bacteria during specimenprocessing.Unsu-
pervised clustering ofCpGmethylationperformedonunpaired tumour
samples revealed that all EBV-positive tumours clustered together and
exhibited extremeCIMP, distinct from that in theMSI subtype8, consis-
tentwithprior reports15 (Fig. 2a).Differencesbetween theEBV-CIMPand
MSI-associated gastric-CIMPmethylationprofiles of tumoursmirrored
differences between these groups in their spectra of mutations (Fig. 1a)
and gene expression (Supplementary Fig. 10.6a). EBV-positive tumours
had a higher prevalence of DNA hypermethylation than any cancers
reportedbyTCGA(SupplementaryFig. 4.6).All EBV-positive tumours
assayed displayed CDKN2A (p16INK4A) promoter hypermethylation,
but lacked theMLH1hypermethylationcharacteristicofMSI-associated
CIMP16. Genes with promoter hypermethylation most differentially
silenced in EBV-positive gastric cancer are shown in Supplementary
Table 4.3.
We observed strong predilection for PIK3CA mutation in EBV-
positive gastric cancer as suggested byprior reports17,18, with non-silent
PIK3CA mutations found in 80% of this subgroup (P5 93 10212),
including 68% of cases withmutations at sites recurrent in this data set
or in the COSMIC repository. In contrast, 3 to 42% of tumours in the
other subtypes displayed PIK3CA mutations. PI(3)-kinase inhibition
therefore warrants evaluation in EBV-positive gastric cancer. PIK3CA
mutations were more dispersed in EBV-positive cancers, but localized
in the kinase domain (exon 20) in EBV-negative cancers (Fig. 2b). The
most highly transcribed EBVviralmRNAs andmiRNAs fell within the
BamH1Aregionof theviral genome(SupplementaryFig. 9.8) andshowed
similar expression patterns across tumours, as reported separately19.
Somatic genomic alterations
To identify recurrently mutated genes, we analysed the 215 tumours
with mutation rates below 11.4 mutations per megabase (Mb) (none
of which were MSI-positive) separately from the 74 ‘hypermutated’
tumours.Within thehypermutated tumours,we excluded fromanalysis
11 caseswithadistinctlyhighermutational burdenabove67.7mutations
perMb(including one tumourwith an inactivatingPOLEmutation20,21)
(Supplementary Information S3.2–3.3), because their large numbers of
mutations unduly influence analysis. We used the MutSigCV22 tool to
define recurrentmutations in the 63 remaininghypermutated tumours
by first evaluating only base substitutionmutations, identifying 10 sig-
nificantly mutated genes, including TP53, KRAS, ARID1A, PIK3CA,
ERBB3,PTEN andHLA-B (SupplementaryTable 3.5).We foundERBB3
mutations in 16 of 63 tumours, with 13 of these tumours havingmuta-
tions at recurrent sites or sites reported inCOSMIC.MutSigCVanalysis
including insertions/deletions expanded the list of statistically signifi-
cantmutated genes to37, includingRNF43,B2M andNF1 (Supplemen-
tary Fig. 3.9). Similarly, HotNet analysis of genes mutated within MSI
tumours revealed common alterations in major histocompatibility
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Figure 1 | Molecular subtypes of gastric cancer. a, Gastric cancer cases are
divided into subtypes: Epstein–Barr virus (EBV)-positive (red), microsatellite
instability (MSI, blue), genomically stable (GS, green) and chromosomal
instability (CIN, light purple) and ordered by mutation rate. Clinical (top) and
molecular data (top and bottom) from 227 tumours profiled with all six
platforms are depicted. b, A flowchart outlines how tumours were classified
into molecular subtypes. c, Differences in clinical and histological
characteristics among subtypes with subtypes coloured as in a, b. The plot
of patient age at initial diagnosis shows the median, 25th and 75th percentile
values (horizontal bar, bottom and top bounds of the box), and the highest and
lowest valueswithin 1.5 times the interquartile range (top andbottomwhiskers,
respectively). GE, gastroesophageal.
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complex class I genes, includingB2M andHLA-B (Supplementary Fig.
11.5–11.7). B2Mmutations in colorectal cancers andmelanoma result
in loss of expression ofHLAclass 1 complexes23, suggesting these events
benefit hypermutated tumours by reducing antigen presentation to the
immune system.
ThroughMutSigCVanalysis of the 215non-hypermutated tumours,
we identified 25 significantlymutated genes (Fig. 3). This gene list again
included TP53, ARID1A, KRAS, PIK3CA and RNF43, but also genes
in the b-catenin pathway (APC and CTNNB1), the TGF-b pathway
(SMAD4 andSMAD2), andRASA1, a negative regulator ofRAS.ERBB2,
a therapeutic target, was significantlymutated, with 10 of 15mutations
occurring at known hotspots; four cases had the S310F ERBB2 muta-
tion that is activating and drug-sensitive24.
In addition to PIK3CA mutations, EBV-positive tumours had fre-
quentARID1A (55%) and BCOR (23%) mutations and only rare TP53
mutations. BCOR, encoding an anti-apoptotic protein, is alsomutated
in leukaemia25 andmedulloblastoma26.Among theCIN tumours,weob-
served TP53mutations in 71% of tumours. CDH1 somatic mutations
were enriched in the genomically stable subtype (37% of cases).CDH1
germlinemutations underlie hereditary diffuse gastric cancer (HDGC).
However, germline analysis revealed only two CDH1 polymorphisms,
neither of which is known to be pathogenic. As in the EBV-subtype, in-
activatingARID1Amutations were prevalent in the genomically stable
subtype. We identified mutations of RHOA almost exclusively in gen-
omically stable tumours, as discussed below.
We analysed the patterns of base changes within gastric cancer tu-
mours and noted elevated rates of C to T transitions at CpG dinucleo-
tides. We observed an elevated rate of A to C transversions at the 39
adenineofAAdinucleotides, especially atAAGtrinucleotides, as reported
inoesophageal adenocarcinoma27. TheA toC transversionswereprom-
inent in CIN, EBV and genomically stable, but as previously observed27,
not in MSI tumours (Supplementary Fig. 3.10).
We identified RHOAmutation in 16 cases, and these were enriched
in the genomically stable subtype (15%of genomically stable cases,P5
0.0039). RHOA, when in the active GTP-bound form, acts through a
variety of effectors, including ROCK1,mDIA and Protein KinaseN, to
control actin-myosin-dependent cell contractility andcellularmotility28,29
and to activate STAT3 topromote tumorigenesis30,31.RHOAmutations
were clustered in two adjacent amino-terminal regions that are pre-
dicted to be at the interface of RHOAwith ROCK1 and other effectors
(Fig. 4a, b). RHOAmutations were not at sites analogous to oncogenic
mutations in RAS-family GTPases. Although one case harboured a
codon 17 mutation, we did not identify the dominant-negative G17V
mutations noted in T-cell neoplasms32,33. Rather, themutations found
in this study may act to modulate signalling downstream of RHOA.
Biochemical studies found that the RHOAY42Cmutation attenuated
activation of Protein Kinase N, without abrogated activation of mDia
orROCK134. RHOAY42,mutated in five tumours, corresponds toY40
onHRAS, a residue whichwhenmutated selectively reducesHRAS ac-
tivation of RAF, but not other RAS effectors35. Given the role of RHOA
in cell motility, modulation of RHOAmay contribute to the disparate
growth patterns and lack of cellular cohesion that are hallmarks of dif-
fuse tumours.
Dysregulated RHO signalling was further implicated by the discov-
eryof recurrent structural genomic alterations.Wholegenome sequenc-
ing of 107 tumours revealed 5,696 structural rearrangements, including
74 predicted to produce in-frame gene fusions (Supplementary Infor-
mationS3.7–3.8).DenovoassemblyofmRNAsequencingdata confirmed
170 structural rearrangements (Supplementary Information S5.4a), in-
cluding two cases with an interchromosomal translocation between
CLDN18 andARHGAP26 (GRAF). ARHGAP26 is aGTPase-activating
protein (GAP) that facilitates conversion of RHOGTPases to theGDP
state andhas been implicated in enhancing cellularmotility34. CLDN18
GSEBV MSI CIN PIK3CA 
PIK3CA mutation
Recurrent or
in COSMIC
Wild type
Other mutations
EBV 
80%
MSI
42%
GS
11%
CIN
3%
0 200 400 600 800 1,000
E
9G
R
38
H
R
88
Q
R
93
W
R
93
Q
10
3−
10
5E
P
V
R
10
8H
K
11
1E
G
11
8D
K
17
9E
Y
18
2H
V
24
3A
N
34
5K
E
36
5K
C
37
8R
N
38
0S
R
41
2Q
C
42
0R
E
45
3K
G
51
2
E
54
2K
E
54
5K
E
54
5G
Q
54
6K
Q
54
6H
E
54
7K
F7
44
I
Q
87
9R
K
94
8E
Y
10
21
H
Y
10
21
C
M
10
43
I
H
10
47
Y
H
10
47
R
ABD RBD C2 Helical Kinase
CDKN2A methylation 
MLH1 methylation
Subtype
1,
31
5 
C
p
G
 s
ite
s
EBV 
CIMP
Gastric 
CIMP Cluster 3 Cluster 4
Tumours
C
p
G
 is
la
nd
P
ro
m
ot
er
N
or
m
al
st
om
ac
h
Yes
Not available
No
Yes
No
MLH1,CDKN2A
methylation
MSI
GS
EBV
CIN
Subtype
0 1
β-value
a
b
Gene promoter,
CpG island probe
Figure 2 | Molecular characteristics of EBV-positive gastric cancers. a, The
heatmap represents unsupervised clustering of DNA methylation at CpG sites
for 295 tumours into four clusters: EBV-CIMP (n5 28), Gastric-CIMP
(n5 77), cluster 3 (n5 73) and cluster 4 (n5 117). Profiles for non-malignant
gastric mucosa are to the left of the tumours. b, The proportion of tumours
harbouring PIK3CA mutation in the molecular subtypes with mutations at
sites noted recurrently in this data set or in the COSMIC database marked
separately (top). Locations ofPIK3CAmutationswith the subtype of the sample
with each mutation colour-coded (bottom).
b
a
–log10(q value)
02060100 0.5 2.0Syn Missense Splice site Nonsense
Frame shift In-frame indel Other non-syn
Syn
Non-syn
EBV GS CIN
0
4
8
12
Mutations
M
ut
at
io
ns
p
er
 M
b
4%
3%
1%
2%
2%
3%
3%
4%
2%
5%
4%
1%
3%
4%
3%
4%
7%
6%
6%
14%
6%
12%
8%
11%
50%
PTPRC
ERBB2
EIF2C4
CNGA4
PLB1
FAM46D
RASA1
SOHLH2
SMAD2
MACF1
CTNNB1
ABCA10
RNF43
BNC2
EYA4
BCOR
APC
MUC6
KRAS
ARID1A
RHOA
PIK3CA
SMAD4
CDH1
TP53
Figure 3 | Significantly mutated genes in non-hypermutated gastric
cancer. a, Bars represent somatic mutation rate for the 215 samples with
synonymous and non-synonymous mutation rates distinguished by colour.
b, Significantly mutated genes, identified by MutSigCV, are ranked by the
q value (right) with samples grouped by subtype. Mutation colour indicates the
class of mutation.
RESEARCH ARTICLE
2 0 4 | N A T U R E | V O L 5 1 3 | 1 1 S E P T E M B E R 2 0 1 4
Macmillan Publishers Limited. All rights reserved©2014
is a componentof the tight junction adhesion structures36. RNAsequenc-
ing data from tumours without whole genome sequencing identified
CLDN18–ARHGAP26 fusions in 9 additional tumours, with twomore
cases showing CLDN18 fusion to the homologous GAP encoded by
ARHGAP6 totalling 13 cases with these rearrangements (Supplemen-
tary Table 5.6).
The fusions linked exon5ofCLDN18 to exon2 (n5 2) ofARHGAP6,
to exon 10 (n5 1), or to exon 12 (n5 10) of ARHGAP26 (Fig. 4c). As
these fusions occur downstream of the CLDN18 exon 5 stop codon,
they appeared unlikely to enable translation of fusion proteins. How-
ever, mRNA sequencing revealed a mature fusion transcript in which
theARHGAP26 orARHGAP6 splice acceptor activates a cryptic splice
site within exon 5 of CLDN18, before the stop codon, yielding an in-
frame fusion predicted to maintain the transmembrane domains of
CLDN18 while fusing a large segment of ARHGAP26 or ARHGAP6
to the cytoplasmic carboxy terminus ofCLDN18.These chimaeric pro-
teins retain the carboxy-terminalGAPdomainofARHGAP26/6, poten-
tially affecting ARHGAP’s regulation of RHOA and/or cell motility.
Furthermore, these fusions may also disrupt wild-type CLDN18, im-
pacting cellular adhesion. TheCLDN18–ARHGAP fusionsweremutu-
ally exclusive withRHOAmutations andwere enriched in genomically
stable tumours (62%, P5 1023) (Fig. 4d).Within the genomically sta-
ble subtype, 30% of cases had either RHOA or CLDN18–ARHGAP
alterations. Evaluation of gene expression status in pathways putatively
regulated byRHOAusing the Paradigm-Shift algorithmpredicted acti-
vationofRHOA-drivenpathways (SupplementaryFig. 11.4a–c), suggest-
ing that these genomic aberrations contribute to the invasive phenotype
of diffuse gastric cancer.
SCNA analysis using GISTIC identified 30 focal amplifications, 45
focal deletions, and chromosome arms subject to frequent alteration
(Supplementary Figs 2.3–2.9). Focal amplifications targeted oncogenes
such as ERBB2, CCNE1, KRAS, MYC, EGFR, CDK6, GATA4, GATA6
andZNF217.Additionally,we sawamplificationof thegene that encodes
the gastric stem cell marker CD44 and a novel recurrent amplification
at 9p24.1 at the locus containing JAK2, CD274 and PDCD1LG2. JAK2
encodes a receptor tyrosine kinase and potential therapeutic target.
CD274andPDCD1LG2 encodePD-L1andPD-L2, immunosuppressant
proteins currently being evaluated as targets to augment anti-tumour
immune response. Notably, these 9p amplifications were enriched in
the EBV subgroup (15% of tumours), consistent with studies showing
elevatedPD-L1expression inEBV-positive lymphoid cancers37,38. Eval-
uation ofmRNA revealed elevated expression of JAK2, PD-L1 and PD-
L2 in amplified cases (Supplementary Fig. 2.10).Morebroadly, PD-L1/2
expressionwas elevated in EBV-positive tumours, suggesting that PD-
L1/2 antagonists and JAK2 inhibitors be tested in this subgroup. Focal
deletionswere identified at the loci of tumour suppressors such asPTEN,
SMAD4, CDKN2A and ARID1A. Additional GISTIC analysis on the
four molecular subtypes is detailed in Supplementary Figs 2.5–2.6.
Gene expression and proteomic analysis
Our analysis of each of the expression platforms revealed fourmRNA,
fivemiRNAand threeRPPAclusters (SupplementaryMethods S5–S7).
Some expression clusters are similar across platforms (Supplementary
Methods S10) and/or have correspondence with specific molecular
subtypes. For example, mRNA cluster 1, miRNA cluster 4 and RPPA
cluster 1 have substantial overlap and are strongly associated with gen-
omically stable tumours, both individually and as a group; the 34 cases
with all three assignments were predominantly genomically stable (20/
34, P5 23 1028). Similarly, mRNA cluster 3, miRNA cluster 2 and
RPPA cluster 3 are similar and are associated with the MSI subtype as
a group (12/22,P5 53 1024).However, absolute correspondencebet-
ween expression clusters and molecular subtypes was not always seen.
For example, RPPA cluster 3 showed moderate association with both
MSI andEBV(P5 0.018 andP5 0.038, respectively), andmiRNAclus-
ters each had similar proportions of CIN (no associations with P,
0.05). Overall, the expression data recapitulate features of themolecu-
lar classification, pointing to robustness of this taxonomy.
We analysed mRNA sequence data for alternative splicing events,
findingMET exon 2 skipping in 82 of 272 (30%) cases, associated with
increased MET expression (P5 1024). We also found novel variants
ofMET in which exons 18 and/or 19 were skipped (47/272; 17%; Sup-
plementary Fig. 5.5). Intriguingly, the exons removed by these altera-
tions encode regions of the kinase domain.
Through supervised analysis of RPPA data, we observed 45 proteins
whose expression or phosphorylationwas associatedwith the fourmo-
lecular subtypes (Supplementary Fig. 7.2). Phosphorylation of EGFR
(pY1068)was significantly elevated in theCIN subtype, consistentwith
amplification of EGFRwithin that subtype.We also found elevated ex-
pressionofp53, consistentwith frequentTP53mutation andaneuploidy
in the CIN subtype.
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Integrated pathway analysis
We integrated SCNA andmutation data to characterize genomic alter-
ations in known signalling pathways, including candidate therapeutic
targets (Fig. 5a, b).We focusedonalterations in receptor tyrosine kinases
(RTKs) and RAS and PI(3)-kinase signalling. EBV-positive tumours
contained PIK3CAmutations and recurrent JAK2 and ERBB2 ampli-
fications. Although MSI cases generally lacked targetable amplifica-
tions,mutations inPIK3CA,ERBB3,ERBB2 andEGFRwerenoted,with
manymutations at ‘hotspot’ sites seen in other cancers (Supplementary
Fig. 11.14). Absent fromMSI gastric cancers were BRAFV600Emuta-
tions, commonly seen in MSI colorectal cancer39. Although the geno-
mically stable subtype exhibited recurrentRHOA andCLDN18 events,
few other clear treatment targets were observed. In CIN tumours, we
identified genomic amplifications of RTKs, many of which are amen-
able to blockade by therapeutics in current use or in development. Re-
current amplification of the gene encoding ligandVEGFAwas notable
given the gastric cancer activity of the VEGFR2 targeting antibody
ramucirumab40. Additionally, frequent amplifications of cell cycleme-
diators (CCNE1, CCND1 and CDK6) suggest the potential for thera-
peutic inhibitionof cyclin-dependent kinases (SupplementaryFig. 11.15).
We compared expression within each subtype to that of the other
subtypes, and to non-malignant gastric tissue (n5 29) (Supplementary
Fig. 11.2). We computed an aggregate score for each pathway of the
NCI pathway interaction database41 and determined statistical signifi-
cance by comparisonwith randomly generated pathways (Supplemen-
tary Methods S11). Hierarchical clustering of samples and pathways
(Fig. 5c) revealed several notable patterns, including elevated express-
ion of mitotic network components such as AURKA/B and E2F, tar-
gets ofMYCactivation, FOXM1andPLK1signalling andDNAdamage
response pathways across all subtypes, but to a lesser degree in geno-
mically stable tumours. In contrast, the genomically stable subtype ex-
hibited elevated expression of cell adhesion pathways, including the
B1/B3 integrins, syndecan-1 mediated signalling, and angiogenesis-
relatedpathways. These results suggest additional candidate therapeutic
targets, including the aurora kinases (AURKA/B) and Polo-like (PLK)
family members. The strength of IL-12mediated signalling signatures
inEBV-positive tumours suggests a robust immune cell presence.When
coupled with evidence of PD-L1/2 overexpression, this finding adds
rationale for testing immune checkpoint inhibitors in EBV-positive
gastric cancer.
Discussion
Through this study of the molecular and genomic basis of gastric can-
cer,wedescribe amolecular classification (Fig. 6) that defines fourmajor
genomic subtypesof gastric cancer:EBV-infected tumours;MSI tumours;
genomically stable tumours; and chromosomally unstable tumours. This
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classificationmay serve as a valuable adjunct to histopathology. Impor-
tantly, these molecular subtypes showed distinct salient genomic fea-
tures, providing a guide to targeted agents that should be evaluated in
clinical trials for distinct populationsof gastric cancerpatients.Through
existing testing forMSI andEBVand theuse of emerging genomic assays
that query focused gene sets formutations and amplifications, the clas-
sification system developed through this study can be applied to new
gastric cancer cases.Wehope these resultswill facilitate the development
of clinical trials to explore therapies in defined sets of patients, ultimately
improving survival from this deadly disease.
METHODS SUMMARY
Fresh frozen gastric adenocarcinoma and matched germline DNA samples were
obtained from295 patients under IRB approved protocols. Genomicmaterial and
(when available) protein were subjected to single nucleotide polymorphism array
somatic copy-number analysis,whole-exomesequencing,mRNAsequencing,miRNA
sequencing, array-basedDNAmethylationprofiling and reverse-phaseprotein arrays.
A subset of samples was subjected to whole-genome sequencing. Initial analysis
centredon thedevelopment of a classification scheme for gastric cancer. Subsequent
analysis identified key features from each of the genomic/molecular platforms,
looking both for features found across gastric cancer and those characteristic of
individual gastric cancer subtypes. Primary and processed data are deposited at
the Data Coordinating Center (https://tcga-data.nci.nih.gov/tcga/tcgaDownload.
jsp); primary sequence files are deposited in CGHub (https://cghub.ucsc.edu/).
Sample lists, and supporting data can be found at (https://tcga-data.nci.nih.gov/
docs/publications/stad_2014/).
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